De-escalation Misses the Mark in Inflammatory Breast Cancer

Published Date: 13 May 2026

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

Read Full News

Latest News

Sequencing Method Flags AML Relapse Risk Around Transplant

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Does Maintenance Therapy Extend Life in mCRC?

Maintenance therapy is linked to longer overall survival after first-line bevacizumab-based combination chemotherapy in patients with metastatic colorectal cancer, a study finds.

Preschoolers With Cancer Have Poor Motor Skills

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

Todays Updates

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Todays Updates

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Latest News

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Maintenance therapy is linked to longer overall survival after first-line bevacizumab-based combination chemotherapy in patients with metastatic colorectal cancer, a study finds.

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

News All Time

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Breast Density Laws Fall Short Raising Additional Screening

State mandates requiring insurance coverage for additional breast cancer scans for those with dense breasts are failing to boost usage.

Is Shorter Radiation Linked to Lymphedema in Breast Cancer?

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

Defibrotide Prophylaxis May Reduce SOS Risk After HSCT

A study evaluates whether defibrotide prophylaxis during HSCT reduces the risk for sinusoidal obstruction syndrome in children with relapsed or refractory B-ALL receiving prior inotuzumab.

Recommended News For You

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

Pooled Cord Blood Transplants Achieve Near-Perfect Results in Early Trial

An understudied type of breast cancer poses a lurking threat

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

Alternative breast imaging techniques beyond mammography.

Does Maintenance Therapy Extend Life in mCRC?

Asandeutertinib Tops Osimertinib for NSCLC With Brain Mets

Recommended Articles For You

Tremelimumab: A Potential Breakthrough in Cancer Treatment 

How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies 

Essential Strategies in Hematology for Healthcare Excellence 

An Overview Of Daunorubicin: What Is It Used For And How Does It Work? 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

De-escalation Misses the Mark in Inflammatory Breast Cancer

2.

10-year study shows tomosynthesis improves breast cancer detection

3.

Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients

4.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

5.

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy

1.

Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning

2.

Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes

3.

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders

4.

Precision Oncology Using Tumor Evolutionary Trajectory Modeling

5.

Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

4.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

5.

Diagnosis and Management in Hematology

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot